Effect of blood pressure and glycemic control on the plasma cell-free DNA in hemodialysis patients
Kidney Research and Clinical Practice · 2015-12 · 34 (4) · 201-206
DOI: 10.1016/j.krcp.2015.09.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney Research and Clinical Practice, 2015-12. Verfasst von Da Wun Jeong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health and Welfare.
Abstract (Originalsprache)
BACKGROUND: The plasma levels of cell-free DNA (cfDNA) are known to be elevated under inflammatory or apoptotic conditions. Increased cfDNA levels have been reported in hemodialysis (HD) patients. The aim of this study was to investigate the clinical significance of cfDNA in HD patients. METHODS: A total of 95 patients on HD were enrolled. We measured their predialysis cfDNA levels using real-time EIF2C1 gene sequence amplification and analyzed its association with certain clinical parameters. RESULTS: The mean plasma cfDNA level in the HD patients was 3,884 ± 407 GE/mL, and the mean plasma cfDNA level in the control group was 1,420 ± 121 GE/mL (P < 0.05). Diabetic patients showed higher plasma cfDNA levels compared with nondiabetic patients (P < 0.01). Patients with cardiovascular complications also showed higher plasma cfDNA levels compared with those without cardiovascular complication (P < 0.05). In univariable analysis, the cfDNA level was associated with 3-month mean systolic blood pressure (SBP), white blood cell, serum albumin, creatinine (Cr), normalized protein catabolic rate in HD patients. In diabetic patients, it was significantly correlated with SBP, hemoglobin A1c, and serum albumin. In multivariate analysis, SBP was the independent determinant for the cfDNA level. In diabetic patients, cfDNA level was independently associated with hemoglobin A1c and SBP. CONCLUSIONS: In patients with HD, cfDNA is elevated in diabetic patients and patients with cardiovascular diseases. Uncontrolled hypertension and poor glycemic control are independent determinants for the elevated cfDNA. Our data suggest that cfDNA might be a marker of vascular injury rather than proinflammatory condition in HD patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea.
Förderung
- Ministry of Health and Welfare
Zitieren
APA
Jeong, D. W., Moon, J. Y., Choi, Y. W., Moon, H., Kim, K., Lee, Y. H., Kim, S. Y., Kim, Y. G., Jeong, K. H., & Lee, S. H. (2015). Effect of blood pressure and glycemic control on the plasma cell-free DNA in hemodialysis patients. Kidney Research and Clinical Practice, 34(4), 201-206. https://doi.org/10.1016/j.krcp.2015.09.002
Vancouver
Jeong DW, Moon JY, Choi YW, Moon H, Kim K, Lee YH, et al. Effect of blood pressure and glycemic control on the plasma cell-free DNA in hemodialysis patients. Kidney Research and Clinical Practice. 2015;34(4):201-206. doi:10.1016/j.krcp.2015.09.002
BibTeX
@article{Jeong2015,
author = {Jeong, Da Wun and Moon, Ju-Young and Choi, Young-Wook and Moon, Haena and Kim, Kipyo and Lee, Yu-Ho and Kim, Se-Yeun and Kim, Yang-Gyun and Jeong, Kyung-Hwan and Lee, Sang-Ho},
title = {Effect of blood pressure and glycemic control on the plasma cell-free DNA in hemodialysis patients},
journal = {Kidney Research and Clinical Practice},
year = {2015},
volume = {34},
number = {4},
pages = {201--206},
doi = {10.1016/j.krcp.2015.09.002}
}
EUVIMED